Given the critical role that MALT1 plays in T cell activation and regulation, there is also emerging interest in the use of MALT1 inhibitors in autoimmune and inflammatory diseases, including psoriasis (62–65), colitis (25, 66–68), rheumatoid arthritis (69), and autoimmune encephalitis/multiple sclerosis (25, 70, 71). This evidence concerns the gene MALT1 and autoimmune encephalitis.